Get in Touch
Unit 22, 3rd Floor, No.258, Farbod Building, between North Golestan & North Ramin St., Kashani BLVD, Tehran, Iran, Postal Code 1481874377
+98 21 44045573+98 21 44045547
info@ddaspharma.com
-
It's Not Just About the Patients,It's About People. -
The Greatest Measure of a ChampionIs Their Impact on Another's Life -
We Prefer Long Lasting Business Relationshipto Short Term Success -
Success Begins With a Simple Question:Have We Made a Difference?
About DDAS
Darou Darman Aria Sepahan (DDAS), is a young healthcare import/export company with innovative and talented professionals who dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. DDAS pharma, a private company founded by pharmacists on 2015 in Esfahan, Iran, is committed to advancing the medical care of patients with quality products that make a positive impact on healthcare and lives. Founded by pharmacists who recognized the importance of pain management, DDAS’s top priority is to continue to identify and develop pain treatments, and to educate the healthcare community about responsible pain management. DDAS combines science with compassionate care to provide medical products of value to patients and the healthcare system. We are committed to improving the therapies that healthcare professionals rely on to treat and manage disease. Beyond the medications we make, we dedicate vast resources to educational programs, partnerships, and resources for healthcare professionals, patients, and caregivers. This company believes that our biggest asset is our zeal to achieve the highest quality customer service by delivering world class products and valuable relationship with all manufacturers. We commit ourselves to develop a mutually beneficial long-term relationship between DDAS and other companies which help us deliver our promise of more reliable pharmaceutical products and better treatment.Our Mission
Our Team
Our commitment to changing tomorrow is measured not only by our focus on bringing innovative and effective new medicines
to patients and physicians, but also by the importance we place on the impact we can make within the communities
where we work and live. This business philosophy expresses the company’s goal to contribute to the health
of people around the world through the provision of highly effective and trustworthy pharmaceuticals, while
continuously increasing DDAS’ enterprise value. The DDAS Group seeks to enhance its enterprise value in a
sustainable manner through its worldwide business activities and to gain the trust of all stakeholders, including
its customers, shareholders, employees, and the global community. To achieve this, we must not only continuously
provide stakeholders with value through our business activities, but we must also proactively take measures
to ensure legal compliance and corporate accountability and to conserve the environment, based on our recognition
of our corporate social responsibility.
Samira Khodadoustan - Managing Director - ceo@ddaspharma.com
Safieh Khodadoustan - Qualified Person - commercial@ddaspharma.com
Mohammadreza Tabesh - Technical Manager
Azadeh Kiani - Accountant
Iran Nasri Ashrafi - Production and Quality Consultant - ashrafi@ddaspharma.com
Hadi Esmaeili - Marketing Manager
Alireza Ghobadi - Commercial Expert - ghobadi@ddaspharma.com
Services
DDAS has focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs. We would have a diverse portfolio of products and product candidates, with a focus in the areas of sleep, cardiology, dermatology, immunology, infectious disease, and urology which will help strengthen DDAS ‘ foothold within Iran marketplace and support our overall goal of being a globally competitive company respected for its knowledge and innovation in established franchises. DDAS is also committed to advancements within the field of oncology and other emerging therapeutic areas. We also support commercial products in other therapeutic areas where we can meaningfully address serious medical needs. As part of our unwavering commitment to improve patients’ lives, we are continuing to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing medicines in our portfolio; acquiring commercial products or product candidates that are in late-stage development; and pursuing focused development of our pipeline of differentiated therapies.
Marketed Products:
- Gliclazide ER 30 mg ( Glizidas ER 30)
- Gliclazide ER 60 mg ( Glizidas ER 60)
- Amlodipine/Bisoprolol 5/5 (Ambicard 5/5)
Products in Pipeline:
We currently have 7 products in our pipeline for allergy, fungal disease, diabetes, cardiovascular disease and immune system improvement.